secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001576885-24-000096
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen Q3 net loss $29.8M; cash $258.9M; ALTITUDE-AD enrollment on track for H1 2025
--------------------------------------------------------------------------------

- Net loss of $29.8M for Q3 2024 vs $13.0M in Q3 2023, driven by higher R&D costs ($27.2M vs $11.2M).
- Cash, equivalents and marketable securities of $258.9M as of Sept 30, 2024, expected to fund operations into H1 2027.
- Phase 2 ALTITUDE-AD enrollment for sabirnetug expected to complete in first half of 2025.
- Topline results from Phase 1 subcutaneous sabirnetug study anticipated in Q1 2025.
- Appointed Amy Schacterle, PhD as Chief Regulatory Officer & Head of Quality in November 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000157688524000096/0001576885-24-000096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000157688524000096/abos-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001576885-24-000096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer